Inventiva Publishes phase 2 results of lanifibranor in T2D and MASLD in journal
Inventiva announced the publication of the previously reported results from the phase 2 investigator-initiated 24 week study evaluating lanifibranor (800mg) in 38 patients with type 2 diabetes (T2D) and metabolic dysfunction-associated liver disease (MASLD) in the Journal of Hepatology. The results highlight the candidate's potential in patients with MASH and T2D, and are in line with other studies that have demonstrated its ability to improve glycemic control. This patient population will be a key focus for the company as lanifibranor's glycemic control properties differentiate the candidate vs. the currently approved Rezdiffra (Madrigal, no coverage), and we look forward to completion of recruitment in the phase 3 trial in MASH expected in 1H25. We reiterate our € 7 TP and BUY rating.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.